Quantcast

Latest Oncolytics Biotech Inc. Stories

2011-03-31 06:30:00

CALGARY, March 31 /PRNewswire-FirstCall/ - Dr. Brad Thompson, President and CEO of Oncolytics Biotech Inc. (TSX: ONC) (NASDAQ: ONCY), will present a corporate overview of the Company at the 10(th) Annual Needham Healthcare Conference on Tuesday, April 5(th), 2011 at 10:00 a.m. ET. The conference will take place on April 5(th) and 6(th) at the New York Palace Hotel in New York, NY. A live audio link to the webcast presentation is available at:http://www.wsw.com/webcast/needham44/oncy/,...

2011-03-24 06:30:00

CALGARY, March 24 /PRNewswire/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX: ONC, NASDAQ: ONCY) today announced that it has completed patient enrollment in its U.S. Phase 2 clinical trial (REO 015) using intravenous administration of REOLYSIN in combination with paclitaxel and carboplatin in patients with advanced head and neck cancers. "This study was performed in part to confirm the results of our UK Phase II study, which enrolled a slightly different patient population, and to...

2011-03-17 06:30:00

CALGARY, March 17 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. (TSX:ONC, NASDAQ:ONCY) ("Oncolytics" or the "Company") today announced its financial results and operational highlights for the year ended December 31, 2010. "2010 was marked by the further expansion of our late-stage clinical program, particularly with respect to the addition of randomized trials and new indications," said Dr. Brad Thompson, President and CEO of Oncolytics.  "Both during the year and...

2011-03-03 06:30:00

CALGARY, March 3 /PRNewswire-FirstCall/ - Dr. Brad Thompson, President and CEO of Oncolytics Biotech Inc. (TSX: ONC) (NASDAQ: ONCY), will present a corporate overview of the Company at the 31(st) Annual Cowen and Company Healthcare Conference on Tuesday, March 8(th), 2011 at 8:45 a.m. ET. The conference will take place from March 7(th) to 9(th) at the Marriott Copley Place in Boston, MA. A live audio link to the webcast presentation is available at:...

2011-03-01 17:20:00

CALGARY, March 1 /PRNewswire/ - Oncolytics Biotech Inc. ("Oncolytics" or the "Corporation") (TSX: ONC) (NASDAQ: ONCY) today announced that the Corporation's biggest institutional shareholder, has exercised 1,248,800 warrants, issued in connection with the financing that closed on November 8, 2010, providing the Corporation with proceeds of approximately $7.7 million. Oncolytics now has approximately 71.1 million shares issued and outstanding, and cash on hand and available for...

2011-02-24 06:30:00

CALGARY, Feb. 24 /PRNewswire/ - Dr. Brad Thompson, President and CEO of Oncolytics Biotech Inc. (TSX: ONC) (NASDAQ: ONCY), will participate in a panel discussion at the RBC Capital Markets Healthcare Conference on Wednesday, March 2(nd), 2011 at 9:00 a.m. ET. The conference takes place at the New York Palace Hotel on March 2(nd) and 3(rd), 2011. A live audio link to the webcast presentation is available at:http://www.wsw.com/webcast/rbc129/rbc129.panel1, or on the company's website at...

2011-02-23 06:30:00

CALGARY, Feb. 23 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX: ONC) (NASDAQ: ONCY) announced today that enrollment has been completed in a U.K. translational clinical trial investigating intravenous administration of REOLYSIN in patients with metastatic colorectal cancer prior to surgical resection of liver metastases (REO 013). The principal investigator is Professor Alan Melcher of St. James's University Hospital and the trial is sponsored by the University...

2011-02-16 06:30:00

CALGARY, Feb. 16 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) announced today that enrollment has begun in a 2-Arm randomized Phase II study of carboplatin, paclitaxel plus REOLYSIN((R)) versus carboplatin and paclitaxel alone in the first line treatment of patients with recurrent or metastatic pancreatic cancer. The Principal Investigator is Dr. Tanios Bekaii-Saab, Medical Director of Gastrointestinal Oncology at The Ohio State University...

2011-02-14 06:30:00

CALGARY, Feb. 14 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) today announced preliminary results from a U.S. Phase 2 clinical trial  (REO 017) using intravenous administration of REOLYSIN((R)) in combination with gemcitabine (Gemzar((R))) in patients with advanced pancreatic cancer. The trial is being conducted at the Cancer Therapy & Research Center at The University of Texas Health Science Center at San Antonio (CTRC). The Principal...

2011-02-10 15:00:00

CALGARY, Feb. 10 /PRNewswire-FirstCall/ - Dr. Brad Thompson, President and CEO of Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY), will present a corporate overview of the Company at the 13(th) Annual BIO CEO & Investor Conference on Monday, February 14(th), 2011 at 4:00 p.m. ET. Hosted by the Biotechnology Industry Organization (BIO), the 13(th) Annual CEO & Investor Conference will take place February 14(th) and 15(th) at the Waldorf-Astoria Hotel in New York. A live audio...


Word of the Day
attercop
  • A spider.
  • Figuratively, a peevish, testy, ill-natured person.
'Attercop' comes from the Old English 'atorcoppe,' where 'atter' means 'poison, venom' and‎ 'cop' means 'spider.' 'Coppa' is a derivative of 'cop,' top, summit, round head, or 'copp,' cup, vessel, which refers to 'the supposed venomous properties of spiders,' says the OED. 'Copp' is still found in the word 'cobweb.'
Related